Jasper Therapeutics, Inc. - Class A Common Stock (JSPR)
3.5100
-0.0400 (-1.13%)
NASDAQ · Last Trade: Jul 12th, 12:02 AM EDT
Detailed Quote
Previous Close
3.550
Open
3.560
Bid
3.410
Ask
3.460
Day's Range
3.350 - 3.649
52 Week Range
2.265 - 26.05
Volume
602,525
Market Cap
2.58M
PE Ratio (TTM)
-0.6673
EPS (TTM)
-5.3
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,369,435
Chart
About Jasper Therapeutics, Inc. - Class A Common Stock (JSPR)
Jasper Therapeutics Inc. is a biopharmaceutical company focused on developing innovative therapeutics to address critical unmet medical needs, particularly in the fields of hematology and oncology. The company is committed to advancing transformative therapies that enhance patient outcomes and improve the quality of life through cutting-edge research and development. Jasper Therapeutics leverages its proprietary technologies and expertise to create novel treatments that aim to tackle complex diseases, fostering collaborations to expedite the delivery of its breakthroughs to patients in need. Read More
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) for violations of the securities laws.
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Jasper Therapeutics, Inc. (“Jasper” or the “Company”) (NASDAQ: JSPR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Curious to know what's happening on the US markets one hour before the close of the markets on Monday? Join us as we explore the top gainers and losers in today's session.
Jasper shares drop after updated BEACON study shows strong results but faces disruption from compromised drug product lot and halted pipeline programs.
Let's have a look at what is happening on the US markets in the middle of the day on Monday. Below you can find the top gainers and losers in today's session.
Jasper Therapeutics' SPOTLIGHT study reports 93% clinical response in cold urticaria and symptomatic dermographism. The 120mg dose showed 83% complete response and no severe adverse events. Full data expected by mid-2025.
